Three New Methods for Diagnosing Pancreas Cancer
Information source: University of Copenhagen
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pancreas Cancer
Intervention: Ultrasound and contrast agent (Procedure)
Phase: N/A
Status: Recruiting
Sponsored by: University of Copenhagen Official(s) and/or principal investigator(s): Michael B Nielsen, DMSc, Principal Investigator, Affiliation: Department of Radiology, Section of Ultrasound
Overall contact: Hanne S Grossjohann, MD, Phone: +45 35453419, Email: hannesonder@dadlnet.dk
Summary
The purpose of this project is to evaluate and compare three new methods for diagnosis,
staging, operability evaluation and treatment control of pancreas cancer. The investigators
use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and
Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an
increased metabolism and thus an increased blood flow through healthy pancreas tissue,
however, not in tumor tissue. The investigators hope to be able to use this effect
diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if
an increased diagnostic safety can be reached compared to an older CT scanning method. All
patients will also be examined for the tumor marker CA 19-9. Further, the investigators will
examine if contrast-enhanced ultrasound can contribute with information in treatment control
after either surgery or medical treatment.
Clinical Details
Official title: Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- suspicion of cancer of the pancreas
Locations and Contacts
Hanne S Grossjohann, MD, Phone: +45 35453419, Email: hannesonder@dadlnet.dk
Copenhagen University Hospital, Copenhagen 2100, Denmark; Recruiting Hanne S Grossjohann, MD, Phone: +45 35453419, Email: hannesonder@dadlnet.dk Hanne S Grossjohann, MD, Principal Investigator
Additional Information
Starting date: February 2005
Last updated: February 25, 2009
|